BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lee SC, Tan HT, Chung MCM. Prognostic biomarkers for prediction of recurrence of hepatocellular carcinoma: Current status and future prospects. World J Gastroenterol 2014; 20(12): 3112-3124 [PMID: 24696598 DOI: 10.3748/wjg.v20.i12.3112] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 58] [Article Influence: 7.4] [Reference Citation Analysis]
Number Citing Articles
1 Qiu B, Zhao MF, Yue ZD, Zhao HW, Wang L, Fan ZH, He FL, Dai S, Yao JN, Liu FQ. Combined transjugular intrahepatic portosystemic shunt and other interventions for hepatocellular carcinoma with portal hypertension. World J Gastroenterol 2015; 21(43): 12439-12447 [PMID: 26604651 DOI: 10.3748/wjg.v21.i43.12439] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
2 Li B, Liu A, Wen Y, Yang G, Zhao J, Li X, Mao Y, Li B. The prognostic values of serum markers in hepatocellular carcinoma after invasive therapies based on real-world data. J Clin Lab Anal 2021;35:e23932. [PMID: 34403527 DOI: 10.1002/jcla.23932] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Kong J, Wang T, Shen S, Zhang Z, Yang X, Wang W. A genomic-clinical nomogram predicting recurrence-free survival for patients diagnosed with hepatocellular carcinoma. PeerJ 2019;7:e7942. [PMID: 31687273 DOI: 10.7717/peerj.7942] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Liang YR, Guo Z, Jiang JH, Xiang BD, Li LQ. Thymosin α1 therapy subsequent to radical hepatectomy in patients with hepatitis B virus-associated hepatocellular carcinoma: A retrospective controlled study. Oncol Lett 2016;12:3513-8. [PMID: 27900029 DOI: 10.3892/ol.2016.5121] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
5 Shao C, Liu G, Zhang X, Li A, Guo X. Long Noncoding RNA RMRP Suppresses the Tumorigenesis of Hepatocellular Carcinoma Through Targeting microRNA-766. Onco Targets Ther 2020;13:3013-24. [PMID: 32308432 DOI: 10.2147/OTT.S243736] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
6 Teng CF, Wu HC, Su IJ, Jeng LB. Hepatitis B Virus Pre-S Mutants as Biomarkers and Targets for the Development and Recurrence of Hepatocellular Carcinoma. Viruses 2020;12:E945. [PMID: 32859114 DOI: 10.3390/v12090945] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
7 Tong A, Tan J, Zhang J, Xu F, Li F, Cao C. Overexpression of RYBP inhibits proliferation, invasion, and chemoresistance to cisplatin in anaplastic thyroid cancer cells via the EGFR pathway: TONG et al.. J Biochem Mol Toxicol 2019;33:e22241. [DOI: 10.1002/jbt.22241] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
8 Hao F, Wang N, Wang X, Chen Y, Wang J. Identification of prognostic long non-coding RNA signature with potential drugs in hepatocellular carcinoma. Aging (Albany NY) 2021;13:18789-805. [PMID: 34285143 DOI: 10.18632/aging.203322] [Reference Citation Analysis]
9 Torzilli G, Donadon M, Belghiti J, Kokudo N, Takayama T, Ferrero A, Nuzzo G, Vauthey J, Choti MA, De Santibanes E, Makuuchi M. Predicting Individual Survival After Hepatectomy for Hepatocellular Carcinoma: a Novel Nomogram from the “HCC East & West Study Group”. J Gastrointest Surg 2016;20:1154-62. [DOI: 10.1007/s11605-016-3132-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
10 Shouval D, Friedman SL. Focusing on the past, present, and future of hepatology. J Hepatol. 2014;61:1196-1198. [PMID: 25195549 DOI: 10.1016/j.jhep.2014.08.039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
11 Mu X, Wang X, Wei Y, Wen C, Zhang Q, Xu C, Liu C, Zhang C, Meng F, Zhao N, Gong T, Guo R, Sun G, Li G, Zhang H, Qin Q, Xu J, Dong X, Wang L, Yu B. ApoE-modified liposomes mediate the antitumour effect of survivin promoter-driven HSVtk in hepatocellular carcinoma. Cancer Gene Ther 2020;27:754-67. [DOI: 10.1038/s41417-019-0145-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
12 Jin Y, Liang ZY, Zhou WX, Zhou L. Expression, clinicopathologic and prognostic significance of plasminogen activator inhibitor 1 in hepatocellular carcinoma. Cancer Biomark 2020;27:285-93. [PMID: 31640087 DOI: 10.3233/CBM-190560] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
13 Chen J, Zhao J, Ma R, Lin H, Liang X, Cai X. Prognostic significance of E-cadherin expression in hepatocellular carcinoma: a meta-analysis. PLoS One. 2014;9:e103952. [PMID: 25093414 DOI: 10.1371/journal.pone.0103952] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
14 Jin Y, Liang ZY, Zhou WX, Zhou L. Plasminogen activator inhibitor 2 (PAI2) inhibits invasive potential of hepatocellular carcinoma cells in vitro via uPA- and RB/E2F1-related mechanisms. Hepatol Int 2019;13:180-9. [PMID: 30600477 DOI: 10.1007/s12072-018-9920-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
15 Huang A, Zhang X, Zhou SL, Cao Y, Huang XW, Fan J, Yang XR, Zhou J. Plasma Circulating Cell-free DNA Integrity as a Promising Biomarker for Diagnosis and Surveillance in Patients with Hepatocellular Carcinoma. J Cancer 2016;7:1798-803. [PMID: 27698918 DOI: 10.7150/jca.15618] [Cited by in Crossref: 26] [Cited by in F6Publishing: 32] [Article Influence: 4.3] [Reference Citation Analysis]
16 Liu J, Zong G, Zhang C, Li C, Chen X, Zhang Y. Anxiety and serum catecholamines as predictors of survival and recurrence in hepatocellular carcinoma. Psychooncology 2017;26:1347-53. [PMID: 27862617 DOI: 10.1002/pon.4305] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
17 Liang B, Jia C, Huang Y, He H, Li J, Liao H, Liu X, Liu X, Bai X, Yang D. TPX2 Level Correlates with Hepatocellular Carcinoma Cell Proliferation, Apoptosis, and EMT. Dig Dis Sci 2015;60:2360-72. [PMID: 26025609 DOI: 10.1007/s10620-015-3730-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 5.0] [Reference Citation Analysis]
18 Song W, Zhang J, Zhang J, Sun M, Xia Q. Overexpression of lncRNA PIK3CD-AS1 promotes expression of LATS1 by competitive binding with microRNA-566 to inhibit the growth, invasion and metastasis of hepatocellular carcinoma cells. Cancer Cell Int 2019;19:150. [PMID: 31624469 DOI: 10.1186/s12935-019-0857-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
19 Meng FD, Wei JC, Qu K, Wang ZX, Wu QF, Tai MH, Liu HC, Zhang RY, Liu C. FoxM1 overexpression promotes epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma. World J Gastroenterol 2015; 21(1): 196-213 [PMID: 25574092 DOI: 10.3748/wjg.v21.i1.196] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 42] [Article Influence: 5.9] [Reference Citation Analysis]
20 Dundar HZ, Aksoy F, Aksoy SA, Tasar P, Ugras N, Tunca B, Egeli U, Cecener G, Yerci O, Kaya E. Overexpression of miR-21 Is Associated With Recurrence in Patients With Hepatitis B Virus-Mediated Hepatocellular Carcinoma Undergoing Liver Transplantation. Transplant Proc 2019;51:1157-61. [PMID: 31101191 DOI: 10.1016/j.transproceed.2019.01.089] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
21 Hsu HY, Yu MC, Lee CW, Tsai HI, Sung CM, Chen CW, Huang SW, Lin CY, Jeng WJ, Lee WC, Chen MF. RAM score is an effective predictor for early mortality and recurrence after hepatectomy for hepatocellular carcinoma. BMC Cancer. 2017;17:742. [PMID: 29121890 DOI: 10.1186/s12885-017-3748-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
22 Ocker M. Biomarkers for hepatocellular carcinoma: What’s new on the horizon? World J Gastroenterol 2018; 24(35): 3974-3979 [PMID: 30254402 DOI: 10.3748/wjg.v24.i35.3974] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
23 Li B, Huang P, Qiu J, Liao Y, Hong J, Yuan Y. MicroRNA-130a is down-regulated in hepatocellular carcinoma and associates with poor prognosis. Med Oncol. 2014;31:230. [PMID: 25218269 DOI: 10.1007/s12032-014-0230-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
24 Zhang Y, Lv X, Qiu J, Zhang B, Zhang L, Fang J, Li M, Chen L, Wang F, Liu S, Zhang S. Deep Learning With 3D Convolutional Neural Network for Noninvasive Prediction of Microvascular Invasion in Hepatocellular Carcinoma. J Magn Reson Imaging 2021;54:134-43. [PMID: 33559293 DOI: 10.1002/jmri.27538] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Yu G, Lin J, Liu C, Hou K, Liang M, Shi B. Long non-coding RNA SPRY4-IT1 promotes development of hepatic cellular carcinoma by interacting with ERRα and predicts poor prognosis. Sci Rep 2017;7:17176. [PMID: 29214989 DOI: 10.1038/s41598-017-16781-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
26 Xi S, Peng Y, Minuk GY, Shi M, Fu B, Yang J, Li Q, Gong Y, Yue L, Li L, Guo J, Peng Y, Wang Y. The combination effects of Shen-Ling-Bai-Zhu on promoting apoptosis of transplanted H22 hepatocellular carcinoma in mice receiving chemotherapy. Journal of Ethnopharmacology 2016;190:1-12. [DOI: 10.1016/j.jep.2016.05.055] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
27 Fernandez O, Urrutia M, Bernillon S, Giauffret C, Tardieu F, Le Gouis J, Langlade N, Charcosset A, Moing A, Gibon Y. Fortune telling: metabolic markers of plant performance. Metabolomics 2016;12:158. [PMID: 27729832 DOI: 10.1007/s11306-016-1099-1] [Cited by in Crossref: 56] [Cited by in F6Publishing: 36] [Article Influence: 9.3] [Reference Citation Analysis]
28 Jin Y, Liang ZY, Zhou WX, Zhou L. High MMP14 expression is predictive of poor prognosis in resectable hepatocellular carcinoma. Pathology 2020;52:359-65. [PMID: 32122646 DOI: 10.1016/j.pathol.2020.01.436] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
29 Kuo HH, Lin RJ, Hung JT, Hsieh CB, Hung TH, Lo FY, Ho MY, Yeh CT, Huang YL, Yu J, Yu AL. High expression FUT1 and B3GALT5 is an independent predictor of postoperative recurrence and survival in hepatocellular carcinoma. Sci Rep 2017;7:10750. [PMID: 28883415 DOI: 10.1038/s41598-017-11136-w] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
30 Zhang L, Bluth MH, Bhalla A. Molecular Diagnostics in the Neoplasms of the Pancreas, Liver, Gallbladder, and Extrahepatic Biliary Tract: 2018 Update. Clin Lab Med 2018;38:367-84. [PMID: 29776636 DOI: 10.1016/j.cll.2018.03.003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Jin Y, Liang ZY, Zhou WX, Zhou L. An MMP-based risk score strongly distinguishes prognosis in hepatocellular carcinoma after resection. Future Oncol 2022. [PMID: 35861053 DOI: 10.2217/fon-2021-1558] [Reference Citation Analysis]
32 Guo C, Zhou S, Yi W, Yang P, Li O, Liu J, Peng C. Long non-coding RNA muskelin 1 antisense RNA (MKLN1-AS) is a potential diagnostic and prognostic biomarker and therapeutic target for hepatocellular carcinoma. Exp Mol Pathol 2021;120:104638. [PMID: 33878313 DOI: 10.1016/j.yexmp.2021.104638] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Lin H, Ewing LE, Koturbash I, Gurley BJ, Miousse IR. MicroRNAs as biomarkers for liver injury: Current knowledge, challenges and future prospects. Food Chem Toxicol 2017;110:229-39. [PMID: 29042291 DOI: 10.1016/j.fct.2017.10.026] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
34 Zhu X, Yan M, Luo W, Liu W, Ren Y, Bei C, Tang G, Chen R, Tan S. Expression and clinical significance of PcG-associated protein RYBP in hepatocellular carcinoma. Oncol Lett 2017;13:141-50. [PMID: 28123534 DOI: 10.3892/ol.2016.5380] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
35 Ma L, Tao C, Zhang Y, Abdulhay E. MicroRNA-517c Functions as a Tumor Suppressor in Hepatocellular Carcinoma via Downregulation of KPNA2 and Inhibition of PI3K/AKT Pathway. Journal of Healthcare Engineering 2022;2022:1-9. [DOI: 10.1155/2022/7026174] [Reference Citation Analysis]
36 Ma X, Yu G, Chen X, Xiao Q, Shi Z, Zhang L, Chen H, Zhang P, Ding D, Huang H, Saiyin H, Chen T, Lu P, Wang N, Yu H, Conran C, Sun J, Zheng SL, Xu J, Yu L, Jiang D. MiR-608 rs4919510 is associated with prognosis of hepatocellular carcinoma. Tumor Biol 2016;37:9931-42. [DOI: 10.1007/s13277-016-4897-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
37 Zhang Y, Wang X, Wang H, Jiang Y, Xu Z, Luo L. Elevated Small Nuclear Ribonucleoprotein Polypeptide an Expression Correlated With Poor Prognosis and Immune Infiltrates in Patients With Hepatocellular Carcinoma. Front Oncol 2022;12:893107. [DOI: 10.3389/fonc.2022.893107] [Reference Citation Analysis]
38 Mußbach F, Henklein P, Westermann M, Settmacher U, Böhmer FD, Kaufmann R. Proteinase-activated receptor 1- and 4-promoted migration of Hep3B hepatocellular carcinoma cells depends on ROS formation and RTK transactivation. J Cancer Res Clin Oncol 2015;141:813-25. [PMID: 25373316 DOI: 10.1007/s00432-014-1863-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
39 Zhu W, Li W, Geng Q, Wang X, Sun W, Jiang H, Pu X. Silence of Stomatin-Like Protein 2 Represses Migration and Invasion Ability of Human Liver Cancer Cells via Inhibiting the Nuclear Factor Kappa B (NF-κB) Pathway. Med Sci Monit 2018;24:7625-32. [PMID: 30359340 DOI: 10.12659/MSM.909156] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
40 Zhao ZG, Wang DQ, Hu DF, Li YS, Liu SH. Decreased FOXF1 promotes hepatocellular carcinoma tumorigenesis, invasion, and stemness and is associated with poor clinical outcome. Onco Targets Ther 2016;9:1743-52. [PMID: 27042124 DOI: 10.2147/OTT.S95002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
41 Bei C, Zhang Y, Wei R, Zhu X, Wang Z, Zeng W, Chen Q, Tan S. Clinical significance of CMTM4 expression in hepatocellular carcinoma. Onco Targets Ther 2017;10:5439-43. [PMID: 29180877 DOI: 10.2147/OTT.S149786] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 3.2] [Reference Citation Analysis]
42 Song X, Zhang S, Tian R, Zheng C, Xu Y, Wang T, Bei C, Zhang H, He X, Zhu X, Tan S. Expression and clinical significance of CMTM1 in hepatocellular carcinoma. Open Med (Wars) 2021;16:217-23. [PMID: 33585698 DOI: 10.1515/med-2021-0221] [Reference Citation Analysis]
43 Yu CP, Yu S, Shi L, Wang S, Li ZX, Wang YH, Sun CJ, Liang J. FoxM1 promotes epithelial-mesenchymal transition of hepatocellular carcinoma by targeting Snai1. Mol Med Rep 2017;16:5181-8. [PMID: 28849004 DOI: 10.3892/mmr.2017.7223] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
44 Teng CF, Li TC, Huang HY, Lin JH, Chen WS, Shyu WC, Wu HC, Peng CY, Su IJ, Jeng LB. Next-Generation Sequencing-Based Quantitative Detection of Hepatitis B Virus Pre-S Mutants in Plasma Predicts Hepatocellular Carcinoma Recurrence. Viruses 2020;12:E796. [PMID: 32722114 DOI: 10.3390/v12080796] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
45 Wang J, Wu D, Sun M, Peng Z, Lin Y, Lin H, Chen J, Long T, Li Z, Xie C, Huang B, Feng S. Deep Segmentation Feature-Based Radiomics Improves Recurrence Prediction of Hepatocellular Carcinoma. BME Frontiers 2022;2022:1-12. [DOI: 10.34133/2022/9793716] [Reference Citation Analysis]
46 Cai J, Sun X, Guo H, Qu X, Huang H, Yu C, Wu H, Gao Y, Kong X, Xia Q. Non-metabolic role of UCK2 links EGFR-AKT pathway activation to metastasis enhancement in hepatocellular carcinoma. Oncogenesis 2020;9:103. [PMID: 33277463 DOI: 10.1038/s41389-020-00287-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
47 Zhu X, Qi G, Li C, Bei C, Tan C, Zhang Y, Shi W, Zeng W, Kong J, Fu Y, Tan S. Expression and Clinical Significance of CMTM6 in Hepatocellular Carcinoma. DNA Cell Biol 2019;38:193-7. [PMID: 30562063 DOI: 10.1089/dna.2018.4513] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
48 Tu J, Zhao Z, Xu M, Chen M, Weng Q, Wang J, Ji J. LINC00707 contributes to hepatocellular carcinoma progression via sponging miR‐206 to increase CDK14. J Cell Physiol 2019;234:10615-24. [DOI: 10.1002/jcp.27737] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
49 Wang X, Ren H, Zhao T, Chen J, Sun W, Sun Y, Ma W, Wang J, Gao C, Gao S. Stem cell factor is a novel independent prognostic biomarker for hepatocellular carcinoma after curative resection. Carcinogenesis. 2014;35:2283-2290. [PMID: 25086759 DOI: 10.1093/carcin/bgu162] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
50 Shaw BI, Lucander A, Ravindra KV. Very Late Recurrence of Hepatocellular Carcinoma After Orthotopic Liver Transplantation: Presentation and Management. Transplant Direct 2019;5:e483. [PMID: 31579811 DOI: 10.1097/TXD.0000000000000921] [Reference Citation Analysis]
51 Li W, Zhang S. CKLF-Like MARVEL Transmembrane Domain-Containing Member 3 (CMTM3) Inhibits the Proliferation and Tumorigenisis in Hepatocellular Carcinoma Cells. Oncol Res 2017;25:285-93. [PMID: 27629543 DOI: 10.3727/096504016X14732523471442] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
52 Wengert GJ, Bickel H, Breitenseher J, Ba-Ssalamah A. [Primary liver tumors : hepatocellular versus intrahepatic cholangiocellular carcinoma]. Radiologe 2015;55:27-35. [PMID: 25575724 DOI: 10.1007/s00117-014-2705-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
53 Shen S, Kong J, Qiu Y, Yang X, Wang W, Yan L. Identification of core genes and outcomes in hepatocellular carcinoma by bioinformatics analysis. J Cell Biochem 2019;120:10069-81. [PMID: 30525236 DOI: 10.1002/jcb.28290] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 7.3] [Reference Citation Analysis]
54 Cui C, Lu Z, Yang L, Gao Y, Liu W, Gu L, Yang C, Wilson J, Zhang Z, Xing B, Deng D, Sun ZS. Genome-wide identification of differential methylation between primary and recurrent hepatocellular carcinomas: GENOME-WIDE IDENTIFICATION OF DIFFERENTIAL METHYLATION. Mol Carcinog 2016;55:1163-74. [DOI: 10.1002/mc.22359] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
55 Gabrielson A, Wu Y, Wang H, Jiang J, Kallakury B, Gatalica Z, Reddy S, Kleiner D, Fishbein T, Johnson L, Island E, Satoskar R, Banovac F, Jha R, Kachhela J, Feng P, Zhang T, Tesfaye A, Prins P, Loffredo C, Marshall J, Weiner L, Atkins M, He AR. Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC. Cancer Immunol Res. 2016;4:419-430. [PMID: 26968206 DOI: 10.1158/2326-6066.cir-15-0110] [Cited by in Crossref: 126] [Cited by in F6Publishing: 103] [Article Influence: 21.0] [Reference Citation Analysis]
56 Wang F, Ying HQ, He BS, Pan YQ, Deng QW, Sun HL, Chen J, Liu X, Wang SK. Upregulated lncRNA-UCA1 contributes to progression of hepatocellular carcinoma through inhibition of miR-216b and activation of FGFR1/ERK signaling pathway. Oncotarget. 2015;6:7899-7917. [PMID: 25760077 DOI: 10.18632/oncotarget.3219] [Cited by in Crossref: 235] [Cited by in F6Publishing: 258] [Article Influence: 39.2] [Reference Citation Analysis]
57 Martins AMA, Garcia JHP, Eberlin MN. Mass Spectrometry as a Clinical Integrative Tool to Evaluate Hepatocellular Carcinoma: Moving to the Mainstream. Expert Rev Gastroenterol Hepatol 2019;13:821-5. [PMID: 31382786 DOI: 10.1080/17474124.2019.1651643] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
58 Ma X, Zhou L, Zheng S. Transcriptome analysis revealed key prognostic genes and microRNAs in hepatocellular carcinoma. PeerJ 2020;8:e8930. [PMID: 32296612 DOI: 10.7717/peerj.8930] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
59 Guo Z, Shi H, Li C, Luo Y, Bi S, Yu R, Wang H, Liu W, Zhu J, Huang W, Song L. Identification and Characterization of a Novel Protein ASP-3 Purified from Arca subcrenata and Its Antitumor Mechanism. Mar Drugs 2019;17:E528. [PMID: 31505835 DOI: 10.3390/md17090528] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
60 Yuan W, Yang M, Zhu Y. Development and validation of a gene signature predicting the risk of postmenopausal osteoporosis. Bone Joint Res 2022;11:548-60. [PMID: 35920104 DOI: 10.1302/2046-3758.118.BJR-2021-0565.R1] [Reference Citation Analysis]